How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control.
about
Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North AmericaIsoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized TrialsImpact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapyDetection of Mycobacterium tuberculosis from the stool of HIV sero-positive individuals suspected of pulmonary tuberculosisHealthcare utilization of patients accessing an African national treatment program.The whole is greater than the sum of the parts: recognising missed opportunities for an optimal response to the rapidly maturing TB-HIV co-epidemic in South AfricaThe tuberculosis challenge in a rural South African HIV programme.Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in SenegalIncreasing late diagnosis in HIV infection in South Korea: 2000-2007.Performance of QuantiFERON-TB Gold test compared to tuberculin skin test in detecting latent tuberculosis infection in HIV- positive individuals in Iran.HIV and tuberculosis in Ho Chi Minh City, Vietnam, 1997-2002.Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings.An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS.UNSUSPECTED FATAL DRUG-RESISTANT TUBERCULOSIS IN A CLOSELY MONITORED CHILD: A PLEA FOR IMPROVED SOURCE-CASE TRACING AND DRUG SUSCEPTIBILITY TESTINGHIV-Associated Tuberculosis.Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.Systematic review of TST responses in people living with HIV in under-resourced settings: implications for isoniazid preventive therapy.Epidemiology of HIV-associated tuberculosis.Antiretroviral therapy at a district hospital in Ethiopia prevents death and tuberculosis in a cohort of HIV patients.Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test.Novel developments in the epidemic of human immunodeficiency virus and tuberculosis coinfectionTuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors.Transcriptional profiling of Mycobacterium tuberculosis replicating ex vivo in blood from HIV- and HIV+ subjectsEffect of isoniazid preventive therapy on tuberculosis or death in persons with HIV: a retrospective cohort study.Understanding latent tuberculosis: a moving target.Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individualsPD-1 Expression and Cytokine Secretion Profiles of Mycobacterium tuberculosis-Specific CD4+ T-Cell Subsets; Potential Correlates of Containment in HIV-TB Co-Infection.Differences in antigen-specific CD4+ responses to opportunistic infections in HIV infection.Vitamin D rescues impaired Mycobacterium tuberculosis-mediated tumor necrosis factor release in macrophages of HIV-seropositive individuals through an enhanced Toll-like receptor signaling pathway in vitroAntiretroviral treatment as prevention: impact of the 'test and treat' strategy on the tuberculosis epidemic.Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapyImmune recovery after starting ART in HIV-infected patients presenting and not presenting with tuberculosis in South AfricaTuberculosis after initiation of antiretroviral therapy in low-income and high-income countries.Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, EthiopiaA Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults.Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South AfricaReducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa.The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda.
P2860
Q21521430-EAE367AE-69D3-4533-9FC6-33D8DAE73229Q26778385-E1490ADB-AA5F-47CD-B2EE-B3E28A80C9F6Q28469286-AC2519BD-D13E-424D-A2AB-BCF645B1A770Q28602123-D0C8C532-3E79-4D47-9B84-E9478C76428BQ30402397-D5327A70-4B9E-40D7-BB3A-58A09CA0D0B2Q33287043-11770CF5-C455-404E-869D-D7A6145C3EE5Q33483082-F52F0229-D862-4CD4-8924-EB54D096C29EQ33530558-93B4969E-52E6-4377-BEF7-8F623FA0DD91Q33616426-BFA68B8B-325A-4FD0-BDED-3D8B8370D8A6Q33630884-0FC8A940-1313-4109-8BA7-9BA583B22D17Q33739774-59B624F0-BBAD-4D59-89B1-395E9F212C87Q33776721-B47E9CCD-10BF-45C2-9D94-1974D2CD1B0CQ33795967-DDA4765C-BD72-4C14-8399-D4DD818286B9Q33920318-8D5E68E6-0F9F-4F42-9081-0D17FC009DEBQ34011244-CC4FC0F0-D415-4B0A-BEA0-358D3DBD3AD1Q34058444-06DA0FE7-8890-4DF4-828F-D4FCC44006F4Q34143510-42F079D9-4590-4170-93FC-6EB183039129Q34222186-8E3A7E3B-5619-4097-9D37-C906B86A7AF4Q34499835-AB226AE5-133A-4CAC-A94B-E2A4E9600BE9Q34519940-180C98EF-92AF-4103-815A-96AA9A9C4950Q34666176-40C86140-7DE4-4A48-9E4D-9D987C6F754FQ34872252-F900ACCB-DC4E-44F2-BCCA-35688EF333A1Q34914625-971D15F0-B125-4DA2-83BA-444531376825Q35124693-65FDF2B4-F387-46D1-B2DE-83198697A66FQ35154909-52AB8A9A-66A6-473F-B6A3-9F172BCE2C4DQ35744636-C47B0609-11AB-406B-AD83-D39660BB6B0EQ35851626-8FD31209-A280-477D-BE5C-F5E2A571B3DDQ35855200-4A850CED-6F65-456E-9A51-263D5FE4F3C2Q35891526-02B294A0-39A7-446D-B461-A9E770DF8DC3Q36082304-43538861-9375-4D9D-AF5F-320C4FB0AF9BQ36506056-B8875898-B9E6-418B-AC57-129656B9276EQ36509003-8F54B80B-464B-4347-A3C6-719FDA081050Q36514050-614431A7-5080-48EB-AD58-E5C05871124CQ36898001-B9515346-C0DB-4956-8455-F574F75D63A8Q36942918-5C487623-B536-466D-BE56-A9F09BCB138CQ37033512-1DE70DC9-4BC5-4B6B-949D-FDEC874F3EB4Q37204894-51FBD511-DD33-457E-9396-558ED66358EBQ37240761-1715170A-4B99-492D-B287-2D343D386DE5Q37285167-B1171277-D986-4AA2-AFE3-8E7666A5D424Q37316263-5C87FF7B-7761-4F22-8E6E-2EDF2960D5FF
P2860
How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
How effectively does HAART res ...... ions for tuberculosis control.
@en
How effectively does HAART res ...... ions for tuberculosis control.
@nl
type
label
How effectively does HAART res ...... ions for tuberculosis control.
@en
How effectively does HAART res ...... ions for tuberculosis control.
@nl
prefLabel
How effectively does HAART res ...... ions for tuberculosis control.
@en
How effectively does HAART res ...... ions for tuberculosis control.
@nl
P50
P1433
P1476
How effectively does HAART res ...... ions for tuberculosis control.
@en
P304
P356
10.1097/01.AIDS.0000176211.08581.5A
P407
P577
2005-07-01T00:00:00Z